Conference Transcript - ROIV 2026-06-09

Goldman Sachs Analyst (moderator), Analyst — Goldman Sachs

Thank you guys for joining us, and good morning, I guess we're still morning, at the Goldman Sachs Global Healthcare Conference. I was thrilled to be joined on stage today with the Chief Executive Officer for Roy Vant, MacLine. And so maybe first, Matt, I just wanted to ask you maybe a little bit of a higher-level question, which is the company was originally developed on the basis of this Vant model. You had distributed and uncorrelated development programs across subsidiaries, but how are you thinking now about kind of the core competencies, of the Roy Vint business model across programs, and how has that model evolved over time?

Matt Gline, CEO

Yeah, thanks, and thanks for having us at the conference. It's great to be here. I can see that you think we're a worse and worse client by the fact that our room keeps getting smaller and smaller, but it's all good. No, look, it's been a fun year. I think there are things we've always been good at, and then there are things I think we've more recently gotten better at, which I think are sort of orthogonal to the model. The truth of the Vant model, which for those who don't know, so we are a 20-ish billion dollar biotech company principally focused on developing and soon to be commercializing a portfolio of late-stage drugs we're really excited about. In that sense, we look like basically every other company, but if you sort of look beneath the surface, we're organized in this weird portfolio model as opposed to a single sort of commanding tool. R&D structure, you're referring to the Vant model, where each program lives within its own company, which makes us a real devil to model. The truth of the model, the truth of why we're set up that way is because every time we deviate from that model, we get worse from an execution perspective. And so it's just having tested everything else, that is how we run our programs best. And I don't think we have any sort of near-term plans to change that. It's just been what's working for us. In terms of what I think we're good at, I think we've always been good at asset selection, at going out into the world and finding programs we're excited to work on. I think we've generally been pretty good at, like, indication selection. I think we've gotten better and better at that over time as we've learned more and more about how we want to do it. And then I think recently we've built some real capabilities in actual just like clinical development and execution that have gotten, again, something we've gotten much better at over the last five or six years that's served us well. And those things, I think, together form the core of what Roivind is, is being able to choose programs, choose smart places, hope smart places to develop those programs, and then hopefully run those programs while we're developing them. And my hope is over the next 12 to 18 months will show that we can also now launch a product in one of those indications as well.

Goldman Sachs Analyst (moderator), Analyst — Goldman Sachs

That is an excellent segue to my first question, which was on the commercialization front. Brepacitinib is your most advanced asset on that front, and you've got Epidufacet now for September of 2026. Maybe you could just refresh us on the highlights of the data in that indication and how you think that could translate into a label.

Matt Gline, CEO

So, Brepacitinib, again, I think everyone's quite familiar with this, but it's a dual inhibitor of JAK1 and TIK2. It's a drug we've had since about 2021 where we enlicensed it at a time where Jack and Hibbers were at the sort of nadir of their own development and our view was we don't know exactly what's going to happen with the class and it turns out the class has done just fine but what we do know is there's an opportunity to develop these drugs in orphan inflammatory disease that nobody else is taking and so that's how we built our franchise The first indication that we chose, the one that we're now staring down the barrel of the duvidate for is dermatomyositis, which is an orphan inflammatory disease It affects probably 70-ish thousand people in the U.S., of whom 40,000 show up in claims data sets right now as actively treated. It's a terrible disease. There's really very little for these patients. Most of them are sort of living on high-dose steroids and immunosuppressants. Some of them go on IVIG, where the treatment paradigm is five days a month in an infusion center, eight hours a day, or are on a variety of off-label things, most of which has failed studies in dermatomyositis. So that's kind of what the setup is. Now, our data, look, our data is great. In a field where very few people have succeeded, great is a complicated bar, but we've shown really nice separation on the endpoint in dermatitis. There's a thing called total improvement scores, one of these composite scores in immunology. Not only that, we got responses quickly, and we were able to maintain those responses against the backdrop of a pretty significant steroid taper, so these patients were both getting a lot better and also reducing their background steroid dose, which is important because these patients come in often on quite high doses of oral prednisone.

Goldman Sachs Analyst (moderator), Analyst — Goldman Sachs

And as you think about what will kind of show up on the label or what you'd like to see show up on the label, what are you framing as kind of like a base or best-case scenario on that front?

Matt Gline, CEO

Yeah, the truth is we haven't had labeling discussions with FDA yet, so I don't really know what's going to be on the label. I don't know that I'm that worried about how the label reads. We're really the first targeted therapy that hopefully will be approved into metamysitis. I think there's a lot of flexibility. I think the FDA is excited about the drug in the sense they're having good constructive conversations with us, but we'll see what they think in terms of labeling when we get there. That's really a discussion to have with them. I think mostly what we need is, look, I think ideally we get a broad dermatomyositis label, let's just approach all of the patients. Even if there were some restrictions on that, I think it would be fine. It would be nice to get some of the data on label around steroid use in the trial. Certainly one of the secondaries involved benefit while on low steroid doses, but also some of the clinical conduct stuff around the stories would be nice to have in there. I think docs are mostly, at this point, getting familiar with the data and the way the trial was run in a way that makes the label a little bit less important. It's a pretty academic field of physicians, but regardless, I think that's all coming. We will have, in all likelihood, Jack-class labeling. There will be a black box on a label for the things that exist on Jack-class black boxes, mortality, et cetera, but nothing that we're particularly concerned about being unusual or mattering much in this patient population.

Goldman Sachs Analyst (moderator), Analyst — Goldman Sachs

You just mentioned that it's a pretty academic kind of group of physicians. I guess how are you thinking about the size of the commercial sales force you need to build, and where are you in terms of hiring that out?

Matt Gline, CEO

Yeah, so we're making great progress. So there's about half of the U.S. patient population, or a little more than half, is treated at 200 referral centers, most of which are academic. It's things like Johns Hopkins and Mayo Rochester and stuff like that, Cleveland Clinic. And about half the population is treated at those 200 centers. we will cover all of those centers and then into the tail of community dorms and rooms we will have a field force numbered in the 10s exactly where in the 10s we haven't said and we've made tremendous progress at hiring those people it's in general a pretty experienced capable sort of medical personnel with a myositis KOL herself before leaving clinical practice to work with us it's a field force that knows in many cases this community a lot of the people who are taking into the field from a medical perspective, worked on the clinical trial and have now moved over into the medical field force for this sort of launch. And so they already had the relationships from clinical trial sites coming in. You know, I think it's been a great process for us.

Goldman Sachs Analyst (moderator), Analyst — Goldman Sachs

And how are you thinking about pricing strategy, particularly given you have a slew of other indications coming behind DM?

Matt Gline, CEO

Look, I think all of the indications that we were studying with BREPO have in common that they are, you know, between, call it, 20,000 and 150,000 patient orphan inflammatory or diseases without a lot of other options, they should all sustain or support pretty similar pricing bands. So I'm not, I think whatever we do here is going to work, within the envelope of the flexibility we have going forward, is going to work just fine. All we've said publicly about price is that IVIG on the low end is a $200,000 a year-ish therapy, and if F. cartigamide is successful in myositis, it'll be a call at $500,000 or $600,000 net price therapy maybe, and so those are reasonable bookends. I think anywhere within that range is still on the table. To be honest, given the size of the patient population, if everyone just models the bottom, then everyone can be pleasantly surprised.

Goldman Sachs Analyst (moderator), Analyst — Goldman Sachs

Under-promised, everyone. So in terms of the, you had just mentioned, sorry, I lost my train of thought, but in terms of the patient population, how are you thinking about what the right peak penetration is, and how do you think about the path to peak, given this is a rare disease, and what would you point to as analogs in that market?

Matt Gline, CEO

Yeah, I don't... The truth is, with 40,000 patients at the price points I just articulated, you don't need very deep penetration to be a great foundational indication. Remember, BREF was in development and three other indications, a lot of other places to go. We will certainly add indications beyond these four. So I don't think we need very high penetration. Incredibly enthusiastic. 30 to much higher than 30% of their patients. any of those numbers would be just fine from a penetration perspective I think I don't have analogs on launch trajectory I think every rare disease is its own thing and I think slow and steady is the right way to think about the launch and any new indication until you have a better sense of how the payer and physician dynamics are going to play out I'll say in terms of market size, first of all DM does feel like a market where the total patient number could grow once there's novel therapies in the market But despite the already relatively high number of diagnosed patients, it's somewhat difficult to diagnose, and you get patients with lupus diagnoses or you get patients with other myositis. So I think there is an opportunity for the patient population to grow. And without intending to give any guidance on trajectory, I'll just say in terms of analogs to the patient population, there are not a whole lot of things you would have said about the myasthenia gravis market in 2019 that you wouldn't say about DM today. Before the introduction of F-Cortigemod, there were about 40,000 MG patients in claims data sets. About 20% of them were on sort of novel therapies, much of which was IVIG. It's like a relatively similar composition, and obviously that market over time has shown itself enthusiastic for a new option. I hope and expect we'll see something similar in DM.

Goldman Sachs Analyst (moderator), Analyst — Goldman Sachs

Great. You mentioned there's three other indications in development. Maybe could you speak to what each of those are and how they match the indication selection strategy you already outlined?

Matt Gline, CEO

Sure. So the other three indications are cutaneous sarcoidosis. Let me go in order. The first next indication is non-infectious uveitis, which is a non-infectious inflammation of the eye. We're focused on back of the eye inflammation. That will read out a registrational data set in the second half of this year, which would then be the second approved indication if all that is successful. That is probably 70,000 to 180,000 patients, depending on how you count it. It's a very messy claims landscape or a very messy diagnostic landscape. It's a little bit hard to know the precise number, but a severe disease, third leading cause of blindness in the United States, low tolerance for optical inflammation. So if our drug works and we have a really good phase two study there, I think that'll be an exciting market and pretty similar in size or maybe even a little bit bigger than DM. The next indication is cutaneous sarcoidosis, where we are beginning a pivotal study this year. We had a phase two data set readout earlier this year, that's a slightly smaller indication, maybe 20,000 to 40,000 patients, but still quite severe, no approved options, really sick patients with a really bad set of inflammatory and potentially permanently disfiguring skin symptoms. So that pivotal program will be ongoing shortly. And then the most recently announced indication is lichen planopilaris, which is a sort of form of lichen planis that involves scarring of the scalp and can involve permanent hair loss, very painful, high concurrent use of opioid pain medications. It's like a really tough disease for the people that have it, and basically nothing approved so far. We're, I think, the leading and potentially only mechanism or only program in late-stage development at this point, so an exciting addition, and that's in sort of a continuous Phase 2-3 study that will start, has started, is enrolling nicely already. Could you speak to the conviction you have

Goldman Sachs Analyst (moderator), Analyst — Goldman Sachs

in the Phase 3 NIU study that's coming based on the data you've presented to date, and if there's any sort of commercially relevant secondary endpoints or bar that you think matter here?

Matt Gline, CEO

Sure. I feel pretty good about the phase three study. I lose sleep over it because it's biotech and you have to lose sleep over everything all the time. It's just the rule. But we had quite good phase two data, which left quite a lot of margin. So the challenge of the phase two data is relatively small end study and didn't have a placebo. And placebos in all of these conditions are variable and have been trending up over time. Humira in their phase three study in NIU. The primary endpoint is a thing called time-to-treatment failure, which is what it sounds like. It's how long these patients take to fail treatment. Placebo patients failed in three months and change in the Humira study, and the drug delivered just under six months of sort of total benefits or two or three extra months over placebo. In our phase two study, it was greater than 12 months. That was as far out as the study went. And so, you know, I think a lot of cushion. Frankly, I don't even think we have to be better than Humira to be commercially successful. Humira fails in a lot of patients, and the Humira, there's about 40,000 TNF patients with NIU now, so even in the, you know, half of those patients who eventually fail, that's a pretty big market, but, and I expect it would grow over time, but I think based on the phase two data, there's certainly a possibility for better than Humira across time treatment failure, across treatment failure rate itself. You know, docs look a lot at endosine fluoroscopy and some of these other measures, and those things will matter commercially as well. So recognizing this is

Goldman Sachs Analyst (moderator), Analyst — Goldman Sachs

somewhat early and you haven't provided guidance, how do you think about the total sales opportunity for this product across the indications that you guys have outlined?

Matt Gline, CEO

Across all of the indications? Look, I think it goes beyond those indications, too. Again, I think if it is inflammatory and has between 20,000 and 150,000 patients, it ought to be an eligible indication for us. I think over time, we could be in quite a large number of diseases. We have IP as it stands out to 2039. If each indication we're in is a low blockbuster indication, you can just start adding things up and finding a $5 to $10 billion drug pretty easily. And so I think as we continue to add indications and continue to find success indication by indication, the opportunity here is very large.

Goldman Sachs Analyst (moderator), Analyst — Goldman Sachs

All right, let's switch gears to Univance programs, IMB-1402. And again, let's start at high level. As you think about the FCR in class and your development strategy there, where do you see unmet need and how did you map the development strategy to that?

Matt Gline, CEO

Yeah, it's interesting. So we had a couple of ideas in mind with our FCRN franchise. One was just that we thought we could build a best-in-class agent. We have a better administration than the other drugs. We have a simple sub-Q injection, low-volume, sort of normal, similar to depiction of other very successful sub-Q medications. And one of the key things in FCRN land is the way these drugs work is by suppressing levels of IgG and therefore autoantibodies. Our view has been consistently, and our clinical data has shown consistently, the deeper you suppress IgG, the better you treat these patients. So the world sort of split into a few different categories. There are indications where others in the FCRN space, especially Argenics, sort of the leader in the space, have carved a path forward, myasthenia gravis, CIDP. You know, I think in those indications, our goal is optimistically to deliver better clinical data and to take share that way, to win share amount of administration. Those are really big markets, and the studies should work. And so it's like an opportunity to have sort of a base level of just even relatively modest penetration of those indications would matter. Then there are two other categories of indications. Indications I am most excited about are places where we have carved out a path either where we were first or where we are now first by dint of the way that we've developed the drug. This includes things like Graves' disease, which is probably what I would call our lead indication, which is a truly massive opportunity. Hundreds of thousands of poorly controlled patients, where I would say there had been, despite the fact that there are hundreds of thousands of patients who have failed every therapeutic option available to them, no modern clinical development had been done in Graves' disease prior to the introduction of our studies, and it feels like we have just a great opportunity to provide a new option to a ton of patients. We're now imitation of the finest form of flattery. We're now the leader of a large number of companies doing different things in Graves' disease, and I think that will also help the market and help us in the long term. But now we've also added to that this sort of late-line multi-mechanism failure, D2TRA, rheumatoid arthritis, where these patients have failed multiple lines of therapy. We are not the first FCRN to be studied there, but I think we have found in our view the right patient population is borne out with our clinical data for a real opportunity in FCRN. I think in both of those we are now kind of the pole position FCRN. And then there's a third category of indications like Sjogren's disease where we're not first, but we're much closer to first than an MG and where we think between the timeline gap being shorter and the quality of our agent, we have a chance of being sort of a class leader or at least close to the front of the pack. Great. You just mentioned the RA data

Goldman Sachs Analyst (moderator), Analyst — Goldman Sachs

from period one, which came in earlier than we expected, and it was definitely pretty impressive. Maybe you would walk through the highlights of that data with an emphasis on contextualizing those results in the context of this patient population. Yes. So this is a study that we ran.

Matt Gline, CEO

It is bluntly a weird study in the design of it. We had watched J&J begin development of nipocalumab in RA. And the thesis behind an FCRN in RA is RA is principally an inflammatory disease and most of the approved drugs are anti-inflammatory drugs. But at least in some subset of RA patients, there is a autoantibody component. That is, it seems like some of these patients have elevated levels of certain autoantibodies that are causal. That was the idea behind development of FCRNs in general. And J&J showed something. They showed that if you suppress IgG, you can deliver at least modest benefit. And what they also showed is that benefit was significantly higher in patients who were positive on autoantibody titers than patients who weren't. And because it is orthogonal to the anti-inflammatory mechanisms, early evidence from the J&J data suggested that the benefit might be preserved even in patients that have failed anti-inflammatories. So we designed a study on that basis that looked at truly refractory patients who have failed at least two of the three late-line classes, JAKs, TNFs, and NIL6s. About 60% of the patients we wound up studying had failed both TNFs and JAKs, which is basically the sickest of the patients, or at least the most refractory of the patients. And what we showed in those patients, and contextually this is in the open-label lead-in portion to a randomized withdrawal study, we showed ACR 20 response rates very high in the 70s. We showed ACR 50 response rates above 50 percent, and we showed ACR 70 response rates in the mid-30s, which even in an open-label study, you just don't see a lot of placebo response in ACR70. And so it's clear that there is real activity there. We selected for a high baseline antibody, autoantibody tire of ACPA, the specific autoantibody that we think is most likely to be causal in the disease. You know, I think in practice, in a multi-mechanism failure population, the data could be much worse than this and still see use because these patients don't have a lot of options. And this data is just pretty exciting data. Okay. Broad brushstrokes,

Goldman Sachs Analyst (moderator), Analyst — Goldman Sachs

knowing that you're still working on it, but what does a phase three kind of have to look like here with respect to trial size, and how quickly can you start moving towards that?

Matt Gline, CEO

That is mostly a question for FDA to answer, and I think there's a pretty wide range of possible answers. We would like to see, given that we are happy to accept restrictions in terms of being late-line, et cetera, smaller studies. The typical RA study is 1,500 patients or 2,000 patients, and FDA has historically been concerned that everyone in RA is trying to move into earlier treatment, and so they want to make sure for the size of the RA population in early-line therapy that the drugs are sort of safe and efficacious. Our view is if you're looking at that later-line market, you should be comfortable from a scientific perspective with smaller studies, hopefully hundreds of patients, and that's certainly the conversation we intend to have with FDA. I think the most likely thing is that we would run a placebo-controlled study of a normal sort of head-to-head versus placebo design, but there's a lot of possibilities, including attempting to replicate the existing phase 2B randomized withdrawal trial. That's just all a conversation for us to have with FDA. It's a conversation that we will have with FDA in the second half of this year and come back hopefully with everything kind of packaged in a bow in terms of what our plan is. One thing I'll say is I think we will be among the first companies to have a discussion with FDA about late-line RA studies, but it's coming. There's CAR-T studies. There's NK-targeted studies. There's T-cell engagers. There's people doing work. and by dint of FCRN being quite a safe mechanism, I think we're in an interesting position where all of those other mechanisms that I mentioned are not going to run 1,500 patient studies. You couldn't possibly. And so I think we get to approach FDA as kind of the first in this category with a willingness to do more than I suspect others in the sort of general indication space are going to be able to do and we can use that flexibility to hopefully have a constructive discussion.

Goldman Sachs Analyst (moderator), Analyst — Goldman Sachs

You mentioned it already, but Graves' disease is definitely the lead indication for the development program for 1402. Maybe you can refresh us on the clinical data to date and how it answers for the unmet need you see in that patient population.

Matt Gline, CEO

So Graves' disease is a disease where you have a way that causes the thyroid to become overactive. Most of them are effectively treatable with a course of an antithyroid drug of some kind. And, in fact, many of them eventually, if you're treated on relatively low doses, a minimazol can get under control and then get off antithyroid drugs. For about 350,000 of these patients or 30,000 of these patients, their journey just can't end there. That is, either they can never get off methimazole or methimazole is insufficient to control their Graves' disease and they continue to relapse and have issues. And those patients, they're sort of stuck at that point. About 20,000 of them a year wind up having their thyroid removed, either surgically or via radiation or radioactive ablation. and, you know, other than that, they just live sick. They live either on high-dose methimazole that's miserable or they live with symptoms of grave disease or both. Our clinical data suggests that for that patient population, we can get a very high proportion of them controlled. In our phase two study at our high dose, over 70% ultimately got controlled and somewhere between 30% and 50% depending on how you count it got off ATDs and controlled. And in fact, of the people who were controlled and off ATDs, not only that, but we were able to drive a remittive benefit where even after some period of time they could get them off our drug and remain off ATDs in control. Remember, these are patients who weren't controllable on ATDs before. So this is a pretty remarkable outcome for the data and, again, paves the way for a real clinical benefit. It's called 350,000 patients who

Goldman Sachs Analyst (moderator), Analyst — Goldman Sachs

otherwise didn't have a path. Great. And you have phase three data next year. I guess what do you need to see there for clinical and also commercial success? And could you talk about the design of the two phase threes you have relative to that?

Matt Gline, CEO

So we're running two studies. One is a relatively straightforward six-month, six-this-month study. The other is a 12-month study where the primary endpoint is at approximately six months, 26 weeks. And the study is designed to allow us to show remit of benefit in the second period. So responders in the first period are then taken off-drug on a re-randomized basis and looked at for remission. So that study will read out effectively after 52 weeks. The other study will read out after 26 weeks. in terms of what we need clinically again first modern therapy ever in grave disease a p-value will do it we think that'll lead to an approvable drug knock wood and that's really all we need I think also for commercial success to be honest again the size of that commercial success and how the competitive field plays out will depend on what we show if we show anything that looks even remotely like our phase two data it will be transformative for tens of thousands or more of these patients I think it's a huge commercial opportunity but even with more modest data than that, I think we can have a big effect on the sickest of these patients.

Goldman Sachs Analyst (moderator), Analyst — Goldman Sachs

You mentioned the size of the number of patients who have need here. I guess, how are you thinking strategically about pricing for this lead indication relative to a broader development

Matt Gline, CEO

path across indications? We haven't given an answer to that question, but I think in general, our mind is on pricing comparably to in the same range as other FCRNs, and this is a refractory population that has no other therapeutic options, and so there are definitely large subsets of that population for which I think that price point could be sustained.

Goldman Sachs Analyst (moderator), Analyst — Goldman Sachs

How do you think about the role of remission in the patient population, and what is your expectation in terms of how long the impact on duration of therapy?

Matt Gline, CEO

Yeah, look, I think on the second question, based on what we know, there will be some patients who can't even get controlled on our drugs. They're better controlled on our drug but not fully controlled on our drug. I suspect there are some patients who can get fully controlled on our drug, potentially in perpetuity, but will need to be on our drug in perpetuity, and some of those patients will continue to require methimazole in addition to our drug to be controlled, and some will not require methimazole, but will require our drug to be controlled. And then I think there are patients who will go into remission. I think that whole spectrum will exist, and so from a duration of therapy perspective, obviously the patients who can get into remission will be shorter duration of therapy, but there will be some patients for whom this is unfortunately just going to be a chronic condition, whatever. Overly simplistically, I think 1402 suppresses IgG by about 80%. if you think the impact is roughly equivalent on T-RABs. So if you're coming in at 5X, the upper limit of normal antithyroid antibodies, then we will get you to within the normal range. If you're coming in at 20X, the upper limit, we won't get you to within the normal range. And I think that's sort of a rough heuristic for how you might think this will evolve over time.

Goldman Sachs Analyst (moderator), Analyst — Goldman Sachs

Okay. And how are you thinking about the emerging competitive clinical landscape? Obviously, there's other FDRNs coming. There's also degraders that have entered the Graves' disease market. and how do you think about those agents?

Matt Gline, CEO

Yeah, as I said earlier, imitation is the finest form of flattery. I think this is a very much you don't have to outrun the bear indication. And what I mean by that is, first of all, we're first. But even more importantly than that, it will be years before novel agents have quote-unquote saturated in Graves' disease. There are hundreds of thousands of patients treated in a variety of settings. I think the main question for everybody approaching grave disease is just like how do we build awareness of novel therapies how do we get out there how do we get patients out of the uneasy existing paradigm and into an opportunity into a space where there are actual treatment options practically speaking so that's the first answer i think a rising tide will lift all boats i think this field is about to be transformed and i don't think it's about sort of jockeying for position versus other competitors and won't be for many many, many years. Of the stuff in development, I think general IgG approaches, other FCRNs, the broad IgG degraders, et cetera, are going to look pretty similar conceptually to one another and what we can do, they can do, and probably vice versa. The degraders, I'd say like the one asterisk there is obviously like they haven't been tested in large-scale clinical trials at this point, so we'll learn more about how that actually plays out in grave disease and generally after we see that data, and there could be some issues, but mostly, if I had to guess, they'll all be sort of fine and pretty similar. Then there are two other approaches that people are taking. One is not autoantibody-driven at all. There's just people working on therapies that either directly affect the TSH receptor in one way or another. There's either small molecules or antibodies. Those approaches may very well treat patients even sicker than the ones we can treat, but they will send patients from hyperthyroid to hypothyroid. And so they'll either need to be carefully titrated or you'll need to concurrently dose synthetic thyroid hormones. So my guess is they will be reserved in many cases for the sicker patients who can't be treated with a more elegant autoantibody-driven mechanism. And then there are a couple of companies now that are working on autoantibody-specific degradation, meaning like T-RAB degraders or whatever. I think that's a really interesting idea. It is the kind of mechanism that in the fullness of time could deliver even better data than we could, but it's just early to know how possible that's going to be and how varied the antibodies are in grave disease is not something we have a very clear answer to scientifically yet.

Goldman Sachs Analyst (moderator), Analyst — Goldman Sachs

I want to switch gears again to Mosley-Siguat, and maybe you could just remind us of the Phase II results that we should expect in the second half of this year and where you get conviction and potentially a positive outcome.

Matt Gline, CEO

Sure. So Mosley-Siguat is our third late-stage drug. This is an inhaled SGC activator, which we're developing in pulmonary hypertension for lung disease patients. This is a mechanism that is a cousin to SGC stimulation, which was the basis of this drug called Adempus, that was a collaboration between Merck and Bayer that was quite commercially successful in group 1 pulmonary hypertension. We are developing a drug in PHLV as an inhaled formulation. Our phase 2B data comes later this year. PHLV is an indication that has risen in prominence and relevance with the commercial success of Tyveso and with Liquidia now coming into that market as well and Inzimat eventually, all with different formulations of Tuprostanol. It's worth noting that Dempest, the drug I mentioned before, which was a systemic SGC stimulator, failed in PHILD and had some pretty significant safety issues. Our expectation, first of all, what do we know? We know that Mosley in group one pulmonary arterial hypertension patients, healthy volunteers, is a very good local vasodilator that improves cardiac output and lung function, so very deep reductions in PVR. We know that other systemic vasodilators in PHILD, troposinol, for example, don't work. We know that other locally administered inhaled vasodilators, troposinol, for example, do work. The end of those mechanisms is small, but that is where we get our conviction that our drug is good as an inhaled vasodilator in group one patients, that other drugs that have been good as inhaled vasodilator in group one patients have worked in group three, and that other drugs have mechanisms that have failed systemically in Group 3 when administered from a local perspective, administered on an inhaled basis, have worked. That's basically what gives us comfort. There's a lot of uncertainty there, and we won't know if it works until it works. I'll say we have the benefit and the challenge that if the drug works, in hindsight, everyone will say, obviously it worked. It was just as you described, inhaled vasodilators work in Group 3 and systemic vasodilators don't. Everyone will say, obviously it failed. Odempis failed. Why did you think an SGC? Either way, we will look like it was obvious in hindsight, when in fact, on an antecedent basis, who knows?

Goldman Sachs Analyst (moderator), Analyst — Goldman Sachs

There's a reason we play the game, right?

Matt Gline, CEO

That's right.

Goldman Sachs Analyst (moderator), Analyst — Goldman Sachs

So in terms of investing further behind this program, what do you need to see from the phase two becoming to kind of move into Pivotal?

Matt Gline, CEO

The reason, I guess you were implying, is fear or gambling addiction or something.

Goldman Sachs Analyst (moderator), Analyst — Goldman Sachs

I'm not sure.

Matt Gline, CEO

The hope of helping patients. Sorry, what do we need to see here? Look, I think if you can improve cardiac output in these patients in a properly sized phase three study, it will benefit them clinically on measures like six-minute walk. This study is not powered for six-minute walk. I don't expect to see a p-value in six-minute walk. I don't even know what kind of delta we're going to be able to put up in six-minute walk. It would be nice to see some kind of trend. But the truth is, if we see significant benefits in PVR and cardiac output, the rest will follow. And so as long as we see that and a safe agent in phase two B, we will run a phase three It would be nice to see something in a six-minute walk. We're not looking for p-value. I'm not expecting a p-value. I'm going to say that a million times in public settings so that the goofy Bloomberg chats about this will at least have me to contend with. So mostly I think we're looking for good safety, the kind of thing that would support a registrational program, and a strong benefit on PVR.

Goldman Sachs Analyst (moderator), Analyst — Goldman Sachs

And how are you thinking about positioning of this agent relative to the other things that are in development? You kind of mentioned a bunch of them in PHILD.

Matt Gline, CEO

phil pulmonary phah group one pulmonary hypertension is a polypharmacy market basically every patient in the fullness of time winds up going on every mechanism or at least many many patients do right now only trastinol is approved in phlb i think phlb will evolve the same way these are really sick patients if multiple mechanisms are approved patients will try all of them so this isn't really an us versus them this is a if we present a good compelling option. People will use it. I think given the PVR reductions we saw, given we are a once-daily puff of a DPI, which makes us nice from a form factor perspective relative to the troposinol that are currently on the market or even coming, and given that troposinol causes cough as an on-target side effect, and we shouldn't, I think we have a chance of early first-line use in PHLD. But that said, that's not really important. What's really important is these other agents.

Goldman Sachs Analyst (moderator), Analyst — Goldman Sachs

Significant capital on your balance sheet, and you have an upcoming launch. Can you walk us you the path to profitability from here? Well, I think if our launches are successful,

Matt Gline, CEO

they will be high margin launches and will become profitable. We have not given specific guidance on timing, but I think we've got plenty of cash to get there and shouldn't need any more money to do it. We've been buying back stock pretty consistently and will continue to do so.

Goldman Sachs Analyst (moderator), Analyst — Goldman Sachs

Okay. Speaking of that, could you speak to the capital allocation priorities you have between returning cash to shareholders, business development, and investing behind the existing

Matt Gline, CEO

pipeline. Yeah. So last year, ending the middle of last year, we bought back about a billion and a half dollars of stock at about $10 a share, which has proven a good investment in hindsight. We are now doing further buybacks. We've sort of ramped them up after we settled with Moderna back in March and continue to buy back stock here. That's sort of on the premise that we've articulated for years, that if we can't make it with $4 billion, we probably can't make it with billion dollars and so we feel like we've got some flexibility and then the four billion dollars we've said consistently is more than enough to fund both all of our existing programs to profitability as well as new stuff and new stuff is new indications as yet unannounced for fcrn and brepo and mostly new stuff is business development which we're uh continue to be focused on and one of these days we'll get a deal done and everyone will be excited about it i hope

Goldman Sachs Analyst (moderator), Analyst — Goldman Sachs

in terms of the business development we have one minute left so what kind of criteria are you guys using as you consider these potential opportunities? In general, we like what we like,

Matt Gline, CEO

which is late-stage programs with relatively open competitive fields with a clinical development strategy that we think is interesting and differentiated. So that's most of what we're looking for. It's most of what we've brought in historically. And we continue to see lots of opportunity approximately meeting that description. All right. I think that does it for us today.

Goldman Sachs Analyst (moderator), Analyst — Goldman Sachs

Great. Thank you so much, Matt, for joining us, and thanks to everyone who joined us here and online.

Matt Gline, CEO

Thank you. Appreciate it. Bye. Thank you.